alectinib

Overview

Alectinib is a targeted anticancer therapy used primarily in ALK receptor tyrosine kinase–positive non-small-cell lung cancer (NSCLC). It is a second-generation ALK inhibitor designed to suppress oncogenic signaling driven by ALK rearrangements, a molecular subtype that defines a clinically important subset of lung cancers. By inhibiting ALK signaling, alectinib helps reduce tumor cell proliferation and disease progression in ALK-positive malignancies.

Clinically, alectinib has become an important treatment option in both advanced and resected early-stage ALK-positive NSCLC. Recent research continues to evaluate its comparative effectiveness, resistance mechanisms, toxicity profile, and potential interactions with immune and cellular pathways such as PD-1/PD-L1 signaling, cancer-associated fibroblasts, and autophagy-related processes.

Focus of Latest Publications

Recent publications on alectinib have focused on its role in ALK-positive non-small cell lung cancer across treatment settings, from early-stage adjuvant therapy to postoperative recurrence and resistance biology. In the randomized ALINA trial exploratory analysis, investigators examined whether the disease-free survival benefit of adjuvant alectinib versus chemotherapy was consistent across surgical characteristic subgroups and when patients were reclassified by AJCC/UICC 8th edition staging. Separate cost-effectiveness analyses compared adjuvant alectinib with platinum-based chemotherapy in the United States and first-line alectinib with lorlatinib in Italy, reflecting continued interest in the clinical and economic positioning of alectinib within ALK-targeted treatment strategies.

Several studies addressed outcomes after surgery or recurrence. A retrospective multicenter series of patients with postoperative recurrent ALK-rearranged lung adenocarcinoma reported durable efficacy with first-line alectinib after recurrence, with median progression-free survival not reached and a 5-year PFS rate of 58.3%, alongside acceptable safety. These findings support the use of alectinib as a targeted option in the recurrent setting, although the authors noted that prospective studies are needed to define the optimal timing of ALK-TKI initiation.

Other recent work examined alectinib in mechanistic and translational contexts. One study using in-vitro non-small cell lung cancer models compared growth and drug-response models under conditions with and without alectinib and cancer-associated fibroblasts, finding that alectinib altered competitive dynamics and promoted competitive exclusion, whereas cancer-associated fibroblasts favored coexistence of resistant and sensitive cells. Another study investigated alectinib-induced toxicity and identified liver-originated selective autophagic degradation of BTD as a mechanism underlying concurrent hepatotoxicity and dermatotoxicity; systemic biotin deficiency was implicated, and biotin supplementation mitigated both toxicities in the reported model.

Resistance-related research also linked alectinib to immune and signaling changes in ALK-rearranged NSCLC. In a study of gilteritinib, the authors reported that gilteritinib could overcome alectinib resistance, inhibit ALK protein levels, and suppress PD-L1 and CD8 co-expression in cell and animal models. Together, these publications portray alectinib as a central ALK-targeted therapy with ongoing relevance in efficacy, resistance, toxicity, and health-economic evaluations.

Key Publications

Jun Which evolutionary game-theoretic model best captures NSCLC dynamics? (PloS one, 2026, PMID 42224394): "The dataset, originally presented by Kaznatcheev et al., includes conditions with and without the drug Alectinib and cancer-associated fibroblasts (CAFs)."
May Liver-originated selective autophagy of BTD by alectinib underlies concurrent hepatotoxicity and Dermatotoxicity. (Autophagy, 2026, PMID 42107012): "Alectinib serves as an indispensable treatment for ALK (ALK receptor tyrosine kinase)-positive non-small-cell lung cancer (NSCLC), yet its hepatotoxicity and dermatotoxicity pose significant clinical concerns due to poorly understood mechanisms."
May Gilteritinib overcomes second‑generation TKIs resistance in ALK‑rearranged non‑small‑cell lung cancer by inhibiting PD‑L1 and CD8 co‑expression. (International journal of molecular medicine, 2026, PMID 42059267): "Gilteritinib can overcome alectinib resistance and inhibit PD-L1 and CD8 co-expression in ALK-rearranged NSCLC, providing a new therapeutic strategy."
Apr Cost-effectiveness analysis of lorlatinib as first-line treatment for anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer in Italy. (Journal of medical economics, 2026, PMID 42043888): "This study evaluated the cost-effectiveness of lorlatinib compared with alectinib as first-line therapy in Italy."
Jun Disease characteristics and treatment outcomes in patients with resected early-stage ALK-positive non-small cell lung cancer from the randomized ALINA trial. (Lung cancer (Amsterdam, Netherlands), 2026, PMID 41996761): "This exploratory analysis investigated whether the disease-free survival (DFS) benefit seen with adjuvant alectinib versus chemotherapy in patients with resected, ALK-positive non-small cell lung cancer (NSCLC) from the phase III ALINA study (NCT03456076) was maintained across surgical characteristic subgroups and when re-classifying patients according to the 8th edition of the Cancer Staging Manual of the American Joint Committee on Cancer (AJCC) and Union for International Cancer Control (UICC)."
Dec Survival outcomes of alectinib in postoperative recurrent ALK-rearranged lung cancer. (Surgery today, 2025, PMID 41342940): "10 patients who received alectinib as first-line therapy for postoperative recurrence between 2014 and 2018, following complete resection at multiple institutions in Japan."
May A Cost-effectiveness Analysis of Adjuvant Alectinib in Patients With Resectable ALK -positive Non-small Cell Lung Cancer in the United States. (American journal of clinical oncology, 2026, PMID 41066159): "We evaluated the cost-effectiveness of adjuvant alectinib versus adjuvant platinum-based chemotherapy for patients with resectable (stage IB to IIIA) ALK + non-small cell lung cancer using a US societal perspective."